Physician profile
Leslee M Lowe
NPI 1497017404
$523.14
in general payments reported to CMS, 2019-2025
10 companies · $82.45 in 2025
The $82.45 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $198 · 2022: $98.64 · 2023: $77.74 · 2024: $66.80 · 2025: $82.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $226.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $113.97 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $92.55 | 2021-2024 | Trintellix |
| Ironshore Pharmaceuticals INC. | $80.01 | 2022-2023 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $52.34 | 2021 | |
| Supernus Pharmaceuticals, INC. | $45.74 | 2021-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $37.90 | 2021 | |
| Lundbeck LLC | $30.87 | 2022-2025 | Rexulti |
| Abbvie INC. | $30.13 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $28.45 | 2022-2024 | Ingrezza |
| Eisai INC. | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslee Lowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.